Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Illumina Inc.

Illumina ( ($ILMN) ) just unveiled an announcement. On April 2, 2026, Illumina announced that board members Frances Arnold, Robert S. Epstein, and ...

Market Cap	$14.67B	P/E Ratio	24.99
52W High	$155.53	52W Low	$68.70
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-52.1%	52W Position	68.5%
Overall Score	39	Value Score	65
Quality Score	42	Technical Score	10

EPS Current Est	$5.13	EPS Next Est	$5.89
EPS Growth Est	+14.8%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ILMN	$128.22	+1.40%	1.06M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ILMN	$128.22	+1.4%	1.06M
3
4
5
6

ILMN

ILMN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Illumina Inc. Data in Excel

Get Illumina Inc. Data in Excel